[Early daunorubicin cardiotoxicity and fatal outcome in a child with acute myeloblastic leukemia (M2)].


The authors report a case of fatal Daunorubicin cardiotoxicity on initial phase of therapy for Acute Myeloblastic Leukemia at cumulative doses (225 mg/mq) considered still safe from the current literature. Despite the interruption of therapy and the interventions performed in support of cardiac functionality the patient came to exitus for heart failure 24… (More)